Latest Administration News

Scout Security reports a significant 48% reduction in operating cash outflows for the June quarter, while holding just $78,000 in cash and advancing talks to acquire Roo Inc. The company is navigating funding challenges amid an ongoing ASX trading suspension.

Scout Security reported a significant 62% reduction in operating cash outflows for Q3 FY2025, while advancing a potential acquisition and partnership opportunities following CES. The company’s cash position remains tight, prompting ongoing capital raising efforts.

Island Pharmaceuticals has won a crucial FDA Type C meeting to discuss fast-tracking its antiviral Galidesivir for Marburg virus treatment, with written feedback expected by November.

Generation Development Group Limited has updated its Dividend Reinvestment Plan price to AUD 6.70 per share, accompanying a fully franked ordinary dividend of 1 cent per share for the half-year ending June 2025.

GR Engineering Services Limited has updated its dividend details for the first half of FY2025, declaring a fully franked dividend of 12 cents per share and setting the Dividend Reinvestment Plan price at AUD 3.897 with a 2.5% discount.

OncoSil Medical’s PANCOSIL Phase 1-2 study reveals promising safety and feasibility for a novel CT-guided pancreatic cancer therapy, with survival outcomes exceeding historical benchmarks.

Imricor Medical Systems has successfully completed a comprehensive Human Factors study for all its devices under FDA review, marking a critical milestone towards U.S. market entry. The extensive 7-month study involved 46 healthcare professionals and tested nine products, underscoring Imricor’s growing momentum in electrophysiology innovation.

Epsilon Healthcare’s manufacturing arm has secured updated GMP certificates covering domestic and EU/UK markets, reinforcing its quality credentials and paving the way for expanded international contract manufacturing.

Javelin Minerals has partnered with MEGA Resources to fully fund and operate the Eureka Gold Project, setting the stage for mining to begin in mid-2026. The deal includes a $4.5 million capital raise and a strategic leadership appointment to drive exploration and production growth.

EMVision Medical Devices has raised $12 million through a placement backed by institutional investors, including strategic partner Keysight Technologies, and launched a Share Purchase Plan to raise up to $2 million from existing shareholders. The capital will support key clinical and regulatory milestones for its neurodiagnostic devices over the next two years.

Nyrada Inc. has released compelling preclinical data showing its drug candidate Xolatryp protects mitochondrial function by reducing calcium overload in brain injury models, bolstering confidence ahead of its Phase IIa trial in acute myocardial infarction.

OzAurum Resources has regained full control of the Mulgabbie North Gold Project feasibility study, initiating inhouse metallurgical testing that has already surpassed industry benchmarks, setting a strong technical foundation for potential gold production.